151 related articles for article (PubMed ID: 33973921)
1. Provider and Patient-panel Characteristics Associated With Initial Adoption and Sustained Prescribing of Medication for Opioid Use Disorder.
Cochran G; Cole ES; Sharbaugh M; Nagy D; Gordon AJ; Gellad WF; Pringle J; Bear T; Warwick J; Drake C; Chang CH; DiDomenico E; Kelley D; Donohue J
J Addict Med; 2022 Mar-Apr 01; 16(2):e87-e96. PubMed ID: 33973921
[TBL] [Abstract][Full Text] [Related]
2. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.
Cole ES; DiDomenico E; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kim JY; Kmiec J; Kelley D; Donohue JM
J Gen Intern Med; 2019 Jun; 34(6):936-943. PubMed ID: 30887440
[TBL] [Abstract][Full Text] [Related]
3. Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.
Peterson L; Murugesan M; Nocon R; Hoang H; Bolton J; Laiteerapong N; Pollack H; Marsh J
PLoS One; 2022; 17(10):e0276066. PubMed ID: 36256662
[TBL] [Abstract][Full Text] [Related]
4. The Role of Primary Care in the Initiation of Opioid Use Disorder Treatment in Statewide Public and Private Insurance.
Gertner AK; Rotter JS; Holly ME; Shea CM; Green SL; Domino ME
J Addict Med; 2022 Mar-Apr 01; 16(2):183-191. PubMed ID: 33973922
[TBL] [Abstract][Full Text] [Related]
5. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Grove LR; Rao N; Domino ME
Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
8. Assessing the impact of drug courts on provider-directed marketing efforts by manufactures of medications for the treatment of opioid use disorder.
Andraka-Christou B; Nguyen T; Bradford DW; Simon K
J Subst Abuse Treat; 2020 Mar; 110():49-58. PubMed ID: 31952628
[TBL] [Abstract][Full Text] [Related]
9. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
[TBL] [Abstract][Full Text] [Related]
10. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
[No Abstract] [Full Text] [Related]
11. Implementation of an office-based addiction treatment model for Medicaid enrollees: A mixed methods study.
Treitler P; Enich M; Bowden C; Mahone A; Lloyd J; Crystal S
J Subst Use Addict Treat; 2024 Jan; 156():209212. PubMed ID: 37935350
[TBL] [Abstract][Full Text] [Related]
12. Contraception claims by medication for opioid use disorder prescription status among insured women with opioid use disorder, United States, 2018.
Goyal S; Monsour M; Ko JY; Curtis KM; Whiteman MK; Coy KC; Cox S; Romero L
Contraception; 2023 Jan; 117():67-72. PubMed ID: 36243128
[TBL] [Abstract][Full Text] [Related]
13. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
14. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
15. Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives.
Kelley AT; Wilcox J; Baylis JD; Crossnohere NL; Magel J; Jones AL; Gordon AJ; Bridges JFP
J Gen Intern Med; 2023 Jul; 38(9):2147-2155. PubMed ID: 36471194
[TBL] [Abstract][Full Text] [Related]
16. Strategies to recruit rural primary care providers to implement a medication for opioid use disorder (MOUD) focused integrated care model.
Cloutier RM; Cole ES; McDonough BL; Lomauro DA; Miller JP; Talbert AL; Bear TM; Bridges NC; Foulds AL; Taber R; Gordon AJ; Cochran GT; Kmiec J; Donohue JM; Kelley D; DiDomenico E; Adair D; Pringle JL
Implement Res Pract; 2023; 4():26334895231152808. PubMed ID: 37091535
[TBL] [Abstract][Full Text] [Related]
17. Retention With Medication for Opioid Use Disorder: The Role of the Primary Care Relationship.
Munger J; Back E
J Addict Med; 2022 Sep-Oct 01; 16(5):577-580. PubMed ID: 35020699
[TBL] [Abstract][Full Text] [Related]
18. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
Smith A; Hansen J; Colvard M
J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder.
Dowd WN; Barch DH; Seibert JH; Mark TL
J Subst Abuse Treat; 2022 Sep; 140():108824. PubMed ID: 35780730
[TBL] [Abstract][Full Text] [Related]
20. Medications For Opioid Use Disorder Increased Among Louisiana Medicaid Enrollees During Policy Reforms, 2018-21.
Sugarman OK; Li W; Saloner B
Health Aff (Millwood); 2024 Jan; 43(1):46-54. PubMed ID: 38190602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
